Brandi Roberts Sells 3,013 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Definium Therapeutics Stock Performance

Shares of NASDAQ DFTX traded up $0.16 during mid-day trading on Friday, hitting $44.95. The company had a trading volume of 12,204,997 shares, compared to its average volume of 2,289,586. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The business’s 50-day simple moving average is $24.13 and its 200-day simple moving average is $19.18. Definium Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.01. The firm has a market cap of $4.48 billion, a P/E ratio of -18.05 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, analysts predict that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DFTX shares. JonesTrading boosted their price objective on Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday. Canaccord Genuity Group set a $60.00 target price on Definium Therapeutics in a research report on Monday. Stifel Nicolaus set a $30.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Oppenheimer set a $60.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday. Finally, Needham & Company LLC raised their price objective on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $47.08.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Institutional Investors Weigh In On Definium Therapeutics

Several large investors have recently modified their holdings of the stock. Boxer Capital Management LLC bought a new stake in Definium Therapeutics in the third quarter valued at $1,928,000. Royce & Associates LP bought a new position in shares of Definium Therapeutics during the third quarter valued at $955,000. Rosalind Advisors Inc. boosted its stake in shares of Definium Therapeutics by 78.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after purchasing an additional 330,000 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Definium Therapeutics in the 3rd quarter worth about $609,000. Finally, Flagship Harbor Advisors LLC bought a new stake in shares of Definium Therapeutics in the 4th quarter worth about $117,000. 27.91% of the stock is currently owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.